ATP Regeneration Patents: Who Leads, Where the Gaps Are 2026
- Filings rose sharply from 2021 to 2024, climbing from 1 to 8 records a year (+700%) before the most recent, still-incomplete years.
- One assignee leads with 14 records, but the ranked field runs 23 companies deep with a long tail of single- and double-digit filers.
- C12N dominates at 87.9% of the 66 records in scope, while C12M bioreactor claims and C07H sugar chemistry sit far behind, hinting at open engineering angles.
Filing growth compares 2021 (1 records) with 2024 (8) — a three-year span. 2024 is the most recent year we treat as complete: publication lags filing by roughly 18 months, so 2025 onwards are still filling in and any growth rate that ends there would understate the field.
What this landscape covers
This landscape tracks patent families addressing ATP regeneration and cofactor recycling in biocatalytic and fermentation contexts — excluding filings framed as human therapy or diagnostic assays. The scope spans 66 published records filed between 2015 and mid-2026, classified predominantly under microorganism and genetic engineering codes (C12N) and fermentation/enzymatic synthesis codes (C12P).
The dataset captures a technology still consolidating around a small set of enzyme-relocation and metabolic-flux control concepts, with academic and specialty-biocatalysis assignees dominant over large pharmaceutical or chemical conglomerates. Filing activity is recent enough that the most current years understate true volume, since publication typically lags filing by around 18 months.
Let an AI agent run this analysis on your own technology
Pick a task. Every answer cites the patents behind it.
Filing trends and technology composition
Two views of the same 66-record dataset: how filing activity has moved year over year, and how records distribute across IPC subclasses.
Filing trend, 2017-2026
Annual filings were negligible before 2021, rose to a peak of 11 records in 2023, and grew from 1 record in 2021 to 8 in 2024 — a +700% increase over that span. 2025 and 2026 figures are still filling in as publications catch up to filing dates.
IPC subclass composition
C12N (microorganisms and genetic engineering) appears in 87.9% of the 66 records, and C12P (fermentation and enzymatic synthesis) in 45.5%. Bioreactor apparatus (C12M), sugar and nucleic acid chemistry (C07H), and enzyme-based measurement (C12Q) each cover under 11% of records, since a record can carry more than one class these shares sum above 100%.
Shares are the percentage of the 66 records in scope. A patent can carry several IPC classes, so the shares add up to more than 100%.
Go deeper on Cofactor Regeneration Engineering — ATP Regeneration Patent Landscape with Eureka
This page is one run against one query. Ask Eureka your own question about cofactor regeneration engineering — atp regeneration patent landscape and every answer comes back with the patent numbers behind it.
Try EurekaMost-cited records in the field
Phosphorylation of phenolic phytochemicals by two enzymes coupled system
A coupled enzyme system pairs a polyphenol phosphorylation synthetase with an ATP regeneration enzyme that regenerates ATP from AMP, phosphorylating a phenolic substrate to improve its water-solubility and bioavailability while cutting net ATP consumption.Filed by National Taiwan University, published 2024-09-26 — illustrative of how ATP regeneration is increasingly claimed as a supporting module bolted onto a separate synthetic reaction rather than as a standalone cofactor-recycling invention.
| # | Publication no. | Patent title | Citations |
|---|---|---|---|
| 1 | US20110275116A1 | Methods for control of flux in metabolic pathways through enzyme relocation | 31 |
| 2 | US20050069991A1 | Method for plasmid preparation by conversion of open circular plasmid to supercoiled plasmid | 31 |
| 3 | US8956833B2 | Methods for control of flux in metabolic pathways through enzyme relocation | 19 |
| 4 | US5302520A | Enzymatic synthesis of isotopically labeled carbohydrates | 17 |
| 5 | WO2014197655A1 | Control of metabolic FLUX in cell-free biosynthetic systems | 14 |
| 6 | US20050084938A1 | Method for plasmid preparation by conversion of open circular plasmid to supercoiled plasmid | 10 |
| 7 | WO1992005270A2 | Enzymatic synthesis of isotopically labeled carbohydrates, nucleotides and citric acid intermediates | 9 |
| 8 | US5227296A | Enzymatic synthesis of isotopically labeled carbohydrates, nucleotides and citric acid intermediates | 2 |
| 9 | WO2025221925A1 | RNA ligase mediated oligonucleotide synthesis | 1 |
| 10 | WO2024134502A1 | Engineered double-strand RNA ligases and uses thereof | 1 |
Citation counts favour older records simply because they have had more time to accumulate citations within the searched corpus; treat them as a signal of influence on the field, not of current commercial relevance.
Each row carries its publication number; clicking a row searches Eureka by that number.
Put your own technology through the same analysis
Eureka on the web
When you want the answer in the next five minutes.
The agent works the prompt against patents and technical literature, citing every source.
Run your analysis now →MCP server & REST API
When it has to run inside your own pipeline.
Patent search, landscape analysis and assignee resolution as MCP tools. Drop them into any agent framework, or call REST directly.
Browse MCP servers →What the numbers mean for filing strategy
Three patterns stand out once the filing trend, technology composition and citation data are read together.
The field is mid-ramp, not mature
Filings grew from 1 record in 2021 to 8 in 2024, with a peak of 11 in 2023. That trajectory reads as an active build-out phase rather than a settled field, and dense filing in the core IPC classes signals occupied claim space rather than technological maturity.
Genetic engineering claims dominate the core
Almost nine in ten records touch C12N, the microorganism and genetic-engineering class, making it the most contested territory in the dataset. C12P fermentation claims follow at 45.5%, leaving apparatus (C12M) and biochemistry-adjacent classes comparatively thin.
Enzyme relocation and plasmid prep set early precedent
The most-cited records in the set concern metabolic flux control through enzyme relocation and plasmid supercoiling conversion — both older filings whose citation counts reflect years of accumulation rather than current filing volume.
One clear leader, then a long tail
The ranked field runs 23 companies deep, with the leader holding 14 records and the fifth-ranked entity down to 5. Momentum by assignee is mixed: several of the most active historical filers show zero filings in the latest tracked year, consistent with the reporting lag rather than a real slowdown.
Eureka can read the same corpus for gaps instead of for coverage: under-claimed branches adjacent to cofactor regeneration engineering — atp regeneration patent landscape, with the prior art for and against each one.
Assignee landscape
The ranked list covers 23 companies with activity in this space, from a university-affiliated leader down to single-filing entrants. No single organisation is close to dominating the field outright.
Academic-anchored leadership
The leading assignee in this dataset holds 14 records, well ahead of the fifth-ranked entity at 5. Its position is reinforced by a strong co-assignee pairing with a specialty biocatalysis company, the strongest such pairing in the dataset at 12 shared records.
Recent activity is uneven across leaders
Several of the most historically active assignees, including a specialty biocatalysis firm and a major pharmaceutical filer, show sharp year-on-year declines or zero filings in the latest tracked year. Given the ~18-month publication lag, this likely reflects incomplete recent-year data more than an actual pullback.
Collaboration is rare and concentrated
Only 4 co-assignee pairs appear across the dataset, and one pairing accounts for the bulk of shared filings. Most assignees file independently, suggesting IP strategy in this niche runs through solo ownership rather than joint ventures.
| Assignee | Recent year | YoY |
|---|---|---|
| Codexis, Inc. | 2 | -60% |
| Novartis AG | 0 | -100% |
| GreenLight Biosciences, Inc. | 0 | — |
| The Board of Trustees of the Leland Stanford Junior University | 0 | — |
| Board of Regents of the University of Texas System | 0 | — |
| Academia Sinica | 0 | — |
| Unitika Ltd. | 0 | — |
| The Regents of the University of California | 0 | -100% |
Where to take this analysis
The dataset points to a field still filling in around a dominant genetic-engineering claim base, with several adjacent branches lightly claimed.
Stress-test freedom to operate
Before committing to a metabolic-flux or enzyme-relocation approach, check the highest-cited records in this set against your specific pathway design; they set the precedent other filings build from.
Run a freedom-to-operate checkWatch the 2025-2026 filings as they land
Because publication lags filing by roughly 18 months, the real shape of 2025 and 2026 activity will only become visible over the next reporting cycles. Revisit the trend before concluding the field has plateaued.
Track filing trends over timeExplore the under-claimed branches
Bioreactor integration and sugar/nucleotide-linked cofactor chemistry carry far fewer records than the core genetic-engineering classes, which may leave room for a differentiated first claim.
Explore white space with EurekaCommon questions about ATP regeneration patents
ATP regeneration refers to enzymatic or engineered systems that continuously replenish adenosine triphosphate consumed during a biocatalytic or fermentation reaction, avoiding the cost of supplying stoichiometric ATP directly. It matters for patents because claims in this space typically bundle a regeneration module (an enzyme or pathway that regenerates ATP from ADP or AMP) with a separate primary reaction, such as phosphorylation or biosynthesis. This dataset shows the concept is most often claimed alongside microorganism or genetic-engineering elements (C12N) rather than as a standalone invention, which shapes how novelty gets argued during prosecution.
The ranked assignee list in this dataset covers 23 companies, with the top-ranked entity holding 14 records and a clear drop-off to 5 records by the fifth position. The leader is a university, and its strongest collaborative link is a co-assignee pairing with a specialty biocatalysis company, the single strongest pairing found in the data. Beyond the top few, filing activity thins into a long tail of organisations with only one or two records, which is typical of a field still in its growth phase rather than one dominated by a handful of large incumbents.
Yes, based on the years that can be treated as complete: filings grew from 1 record in 2021 to 8 in 2024, a +700% increase, with a peak of 11 records in 2023. Filings recorded for 2025 and 2026 appear lower only because publication typically lags filing by around 18 months, so those years are not yet fully populated. Read the recent uptick as a genuine expansion phase rather than a plateau, and expect the 2025-2026 counts to rise as more records publish.
The dominant class is C12N, covering microorganisms and genetic engineering, present in 87.9% of the 66 records in this dataset. C12P, fermentation and enzymatic synthesis, follows at 45.5%. Smaller but present classes include C12M for bioreactor and enzyme apparatus, C07H for sugar and nucleic-acid chemistry, and C12Q for enzyme- or DNA-based measurement, each under 11%; because a single record can carry multiple classes, these percentages sum to well above 100%.
The classes with the lowest record counts relative to the core C12N/C12P claims are C12M (bioreactor and apparatus integration), C07H (sugar and nucleotide-linked cofactor chemistry), C07K (peptide-linked applications) and C12Q (inline enzymatic assay coupling), each covering well under 11% of the 66 records. These thinner branches suggest room for claims that integrate ATP regeneration directly into reactor hardware or couple it more tightly to specific downstream chemistries, rather than repeating the enzyme-relocation and metabolic-flux concepts that dominate the most-cited records.
Research Cofactor Regeneration Engineering — ATP Regeneration Patent Landscape in depth with Eureka
Go past this page: query the whole cofactor regeneration engineering — atp regeneration patent landscape corpus yourself, in your own scope.
Every answer comes back with patent numbers you can open.
Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.
Machine translation. Assignee and organisation names originally recorded in Chinese, Japanese or Korean have been rendered into English by an AI translation step so that the tables stay readable. These renderings are best-effort and may not match a company’s registered English name; the original name is what the underlying patent record carries, and it is what any Eureka query launched from this page uses.